Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial
Abstract Background Microvascular blood flow (MBF) impairment in patients with lower extremity arterial disease (LEAD) is associated with more severe major adverse limb events (MALE). The contribution of ticagrelor, a P2Y12 antagonist and an adenosine enhancer, on blood viscosity (BV) and BV-depende...
Main Authors: | Robert S. Rosenson, Qinzhong Chen, Sherwin D. Najera, Prakash Krishnan, Martin L. Lee, Daniel J. Cho |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-019-0882-5 |
Similar Items
-
A Case of Ticagrelor Resistance
by: Jahanzeb Malik
Published: (2021-07-01) -
Ticagrelor
by: Gianluca Airoldi, et al.
Published: (2013-03-01) -
The Role of Ticagrelor in STEMI Fibrinolytic and Its Rationale to Utilize for Indonesian Patients
by: Daniel Tobing, et al.
Published: (2019-09-01) -
Reacción de hipersensibilidad a ticagrelor
by: Jorge Alberto Castro Clavijo, et al.
Published: (2020-02-01) -
Ticagrelor Use in Stroke Patients: Past, Present, and Future
by: Chandra R, et al.
Published: (2021-06-01)